Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-27T05:03:21.700Z Has data issue: false hasContentIssue false

45 - Mesenchymal stem cell transplantation to treat multiple sclerosis

from Section III - Clinical trials of multiple sclerosis therapies

Published online by Cambridge University Press:  05 December 2011

By
Don Mahad ,
Sarah M. Planchon  and
Jeffrey A. Cohen
Edited by
Jeffrey A. Cohen  and
Richard A. Rudick
Jeffrey A. Cohen
Affiliation:
Cleveland Clinic
Richard A. Rudick
Affiliation:
Cleveland Clinic
Get access

Summary

The potent immunomodulatory properties of mesenchymal stem cells (MSCs) are particularly relevant for multiple sclerosis (MS). MSCs inhibit T-cell proliferation stimulated by polyclonal activators, cognate antigen and allogeneic mixed lymphocyte reaction. MSCs inhibit B-cell proliferation in culture via soluble factors, accompanied by inhibition of B-cell differentiation and production of IgM, IgG, and IgA. The property of MSCs relevant to MS is their potential ability to lessen damage and augment repair in numerous tissue injury models. In general, MSC transplantation in humans, including with allogeneic MSCs, has been very well tolerated. The several potential adverse events (AEs) that require close attention in planned trials are: infusion-related toxicity, infection, cancer, ectopic tissue formation, rejection, and autoimmunity. MSCs have potential immunomodulatory, tissue protective, and repair promoting properties. There is rapidly accumulating experience with both autologous and allogeneic MSC transplantation in a number of conditions.

Keywords

placebolesionmagnetic resonance imagingmultiple sclerosishigh dose methylprednisolonecorticosteroidsexpanded disability status scale
Type
Chapter
Information
Multiple Sclerosis Therapeutics , pp. 520 - 534
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×